Bausch Health: RED-C Failure Leaves Blockbuster Xifaxan Without A Successor
Source: SeekingAlpha
2026-01-23 14:35:21 ET
Bausch Health Companies Inc. ( BHC ) stock is off nearly 10% in intraday trading after reporting that its Phase 3 program evaluating "next-gen" rifaximin to delay the first episode of hepatic encephalopathy in patients with cirrhosis failed....
Read the full article on Seeking Alpha
For further details see:
Bausch Health: RED-C Failure Leaves Blockbuster Xifaxan Without A Successor
Bausch Health Companies Inc.
NASDAQ: BHC
BHC Trading
-3.45% G/L:
$5.18 Last:
742,541 Volume:
$5.35 Open:
BHC Latest News
February 23, 2026 08:00:00 am
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
February 19, 2026 08:00:00 am
Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
BHC Stock Data
$2,310,173,034
238,316,487
N/A
76
N/A
Pharmaceuticals
Healthcare
CA
Laval
